Financiere de Tubize SA Overview
Financière de Tubize is the reference shareholder of UCB, one of Europe's leading mid-cap biopharmaceutical companies, holding 36.29% of UCB's share capital at 30 June 2026. Founded in 1928, it federates the descendants of UCB founder Emmanuel Janssen together with like-minded long-term investors, and functions as the governance anchor that has kept UCB independent and Belgian-headquartered through successive transformations — from chemicals and films to epilepsy, and now to a global immunology franchise led by BIMZELX. Tubize itself has no operations: its income is UCB's dividend, its costs are a few million euros of overheads, and since May 2025 it carries no bank debt while retaining €350m of committed credit lines as strategic firepower. Its shares have historically traded at a 35–50% discount to the market value of its UCB stake, making Tubize both a governance vehicle and a leveraged-discount proxy for UCB's equity story.
What the company does. Tubize is a pure mono-holding. Its sole investment is its stake in UCB SA (Simply Wall St company profile; Euronext Cofisem profile). Through its representatives on UCB's Board of Directors, Tubize participates in UCB's strategic choices, monitors UCB's performance and seeks to create long-term shareholder value. Its stated mission, as reflected in its communications, is to provide UCB with a stable reference shareholder so that UCB can pursue long-horizon R&D and growth investments.
Company's own description (paraphrased from its public positioning and WEF organisational profile). Tubize presents itself as the reference shareholder of UCB that brings together the family shareholders descending from founder Emmanuel Janssen and investors who share their long-term vision. The 2025 Chair transition statement extended this to supporting a sustainable biopharma ecosystem in Belgium, the UK and other geographies relevant to UCB (Holthof appointment PR, 29 Apr 2025).
Business model. The economic model is extremely simple:
Revenue model mix. 100% investment (dividend) income; 0% product, service, subscription or licensing revenue. Reported "turnover" is effectively nil (StockAnalysis/TipRanks list total revenue of €13.26k for FY2024, i.e., incidental income).
Value chain position. Tubize sits at the top of UCB's ownership chain as controlling-influence holder (not legal control: Tubize has stated in historical Art.74 filings that it is not subject to exclusive or joint control by any party, and it does not hold a majority of UCB).
Customer types / end markets. Tubize has no customers. Its economic exposure is entirely to UCB's end-markets: immunology (psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa), neurology (epilepsy including rare paediatric epilepsies, myasthenia gravis), bone health (osteoporosis via EVENITY, partnered with Amgen) and rare diseases. UCB generates the majority of its revenue in the United States (GuruFocus business description; UCB HY2026 materials).
Independent characterisation. Tubize is best understood as (1) a governance instrument that entrenches family-anchored, long-term ownership of UCB — the "poison-pill-by-shareholding" that makes an unsolicited takeover of UCB practically impossible without Tubize's consent; and (2) a listed security that gives investors leveraged-to-NAV, discounted exposure to UCB. Its cash-flow policy is deliberately conservative: it distributes roughly half of its profit and retains the remainder to keep the UCB stake at or above ~36% and to maintain financial capacity (€350m credit lines) to defend or increase the stake if UCB issues equity for acquisitions.
Strategy
Stated strategy (themes).
-
Remain UCB's stable reference shareholder at or above ~36%. Historical analyst commentary (Bank Degroof/VFB) records Tubize's stance that it would not fall below its stake threshold and stands ready to buy additional UCB shares if needed.
-
Professionalise governance and add biopharma expertise: new independent Chair (Apr 2025), Vice-Chair for family relations (Aug 2025), two biopharma directors (Sep 2025).
-
Maintain financial firepower ("strategic reserves"): €350m committed credit lines renegotiated effective 1 Jan 2026 while carrying zero drawn debt; covenants limit financial debt to 30% of the market value of pledged UCB shares (TUB HY2026 report). Quartr's event summary of Tubize's H2 2025 communication highlights strong long-term TSR and strategic reserves to support UCB's growth while maintaining a 36% stake.
-
Progressive dividend: Tubize dividend raised every year shown (€0.86 → €0.97 → €1.04 → €1.08 for FY2022–FY2025).
-
Ecosystem role: support a sustainable biopharma ecosystem in Belgium, the UK and other geographies relevant to UCB (Holthof statement).
Initiatives in last 24 months.
ESG commitments / cost programmes. None separately announced by Tubize.
Medium-term targets. Tubize issues no financial guidance. Its outlook statement is limited to monitoring geopolitical developments and their possible impact on UCB (TUB HY2026). The relevant targets are UCB's: FY2026 revenue growth in the low- to mid-teens % and adjusted EBITDA growth from mid-teens to low-twenties % at CER (upgraded Jul 2026); BIMZELX peak sales ≥€7bn (UCB HY2026 PR). UCB's earlier medium-term ambition was an adjusted EBITDA margin of at least 30%, already exceeded (40.7% in H1 2026).
Products & Services
Holding level. Tubize has no products, brands, platforms or services. Its "product" for investors is a listed share providing discounted exposure to UCB.
Look-through level — UCB portfolio (value driver of Tubize).
Pricing models for UCB products are not publicly disclosed beyond list prices in individual markets; BIMZELX net price is expected to decline in H2 2026 after UCB secured first-line coverage with a major U.S. PBM effective 1 June 2026 (UCB HY2026 call).
Product Portfolio
| Product | Therapeutic area | Description / mechanism | Key indications | Status / latest datapoint | Source |
|---|---|---|---|---|---|
BIMZELX (bimekizumab) | Immunology | Humanised monoclonal antibody inhibiting IL-17A and IL-17F | Plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa | H1 2026 net sales €1,528m (vs €799m H1 2025, +91%); peak sales guidance raised to ≥€7bn; four head-to-head superiority trials incl. BE BOLD vs risankizumab in PsA; protection to 2037 | UCB HY2026 PR; HY2026 call |
CIMZIA (certolizumab pegol) | Immunology | Anti-TNF PEGylated Fab' | RA, Crohn's, PsA, axSpA, psoriasis | — | — |
EVENITY (romosozumab) | Bone | Anti-sclerostin antibody, co-developed/commercialised with Amgen | Severe osteoporosis | One of five growth drivers | UCB FY2025 PR |
FINTEPLA (fenfluramine) | Neurology (rare epilepsy) | Serotonergic agent, acquired with Zogenix (2022) | Dravet syndrome, Lennox-Gastaut syndrome; positive Ph3 GEMZ in CDKL5 deficiency disorder (Jun 2025) | Growth driver; LOE not before 2033 | UCB FY2025 PR; HY2026 call |
RYSTIGGO (rozanolixizumab) | Neurology / rare | Anti-FcRn monoclonal antibody | Generalised myasthenia gravis; MOG-AD under study | Growth driver | UCB HY2026 PR |
ZILBRYSQ (zilucoplan) | Neurology / rare | Subcutaneous peptide C5 inhibitor | Generalised myasthenia gravis | Growth driver | UCB HY2026 PR |
KYGEVVI (doxecitine and doxribtimine) | Rare disease | Nucleoside therapy | Thymidine kinase 2 (TK2) deficiency | Approved in the U.S. (reported in FY2025 PR) | UCB FY2025 PR |
BRIVIACT (brivaracetam) | Neurology | SV2A ligand antiepileptic | Partial-onset seizures | Loss of exclusivity in 2026 weighing on H2 2026 | UCB HY2026 call summary |
VIMPAT (lacosamide) | Neurology | Antiepileptic | Partial-onset seizures | Post-LOE (generics) [recalled] | — |
KEPPRA (levetiracetam) | Neurology | Antiepileptic | Epilepsy | Mature/generic [recalled] | — |
NAYZILAM / STACCATO alprazolam (pipeline) | Neurology | Rescue therapies for seizure clusters / prolonged seizures | Seizure emergencies | STACCATO alprazolam headline results expected 2026 | UCB FY2025 PR |
Dapirolizumab pegol (pipeline) | Immunology | Anti-CD40L, partnered with Biogen | Systemic lupus erythematosus | Phase 3 | UCB FY2025 PR (Biogen partnership footnote) |
Bepranemab (pipeline) | Neurology | Anti-tau antibody | Early Alzheimer's disease | Ph2a: primary endpoint missed, positive secondary endpoints | UCB HY2025 PR |
Minzasolmin (pipeline) | Neurology | Alpha-synuclein misfolding inhibitor | Parkinson's disease | Ph2a reported positive results (per FY2025 PR text) | UCB FY2025 PR |
Cizutamig (pipeline) | Immunology | T-cell engager from Candid Therapeutics acquisition | Autoimmune diseases | Early data described as promising | UCB HY2026 call |
Rezanecel (pipeline) | Neurology | Cell therapy from Neurona acquisition | Drug-resistant epilepsy | Early data described as promising | UCB HY2026 call |
Financial Narrative
Accounting note. Tubize's statutory accounts (Belgian GAAP) record UCB at historical acquisition cost; profit therefore reflects only dividends received less costs, not UCB's earnings. Gross profit, EBITDA and "revenue" concepts are not meaningful; they are presented for template completeness. Figures below combine company press releases (net profit, debt) with StockAnalysis/TipRanks aggregator data (balance sheet lines, operating loss), which are consistent with company figures where they overlap.
Income statement
Sources: Net income FY2022–FY2025 from TUB AR2023, AR2024, AR2025 PRs; FY2021 net income, operating income and EPS from TipRanks income statement (FY2025 EPS computed as €93.2m / 44.51m shares). Börse Stuttgart's DPS figures (0.68 / 0.73 / 0.76) correspond to net-of-30%-withholding amounts of the €0.97 / €1.04 / €1.08 gross dividends — a source discrepancy explained by gross vs net.
Margins. Because turnover is nil, gross, operating, EBITDA and net margins are not meaningful (aggregators display nonsensical figures such as a net margin of ~680,000%). The meaningful efficiency ratio is cost-to-income: FY2024 operating costs of ~€2.24m against ~€96m of dividend income (derived) ≈ 2.3%.
Revenue CAGR. Not meaningful; the relevant growth metric is net profit CAGR FY2021–FY2025 of ~2.7% p.a. (83.6 → 93.2), tracking UCB's dividend progression (+2.3–4.3% p.a.) plus incremental UCB shares and lower interest.
Half-year profile. Because the UCB dividend lands in May and costs accrue evenly, H1 profit exceeds full-year profit:
Sources: TUB HY2025 PR; TUB HY2026 PR and report.
Balance sheet
Sources: StockAnalysis balance sheet (Belgian GAAP data); debt figures confirmed by TUB AR2023/AR2024/AR2025 PRs; book value per share computed (equity / 44.51m shares). At 30 Jun 2026, equity was €1,986.3m and the solvency ratio 99.98% (vs 97.49% at end-2025) (TUB HY2026 report via Quartr).
Market-value view (more relevant than book value).
Sources: TUB ARs/HY PRs (stake %); shares held derived from stake × 194,505,658 UCB shares, cross-checked to Art.74 notifications (70,502,554 shares at 31 Jul 2024; 70,562,935 at 31 Jul 2025); market cap from TUB HY2026 report.
Cash flow
Sources: TUB AR2024/AR2025 PRs (debt movements, UCB purchases, dividends). A formal cash-flow statement is not published in the retrieved materials; FY2023 UCB share purchases (1,043,881 shares) were material but the euro amount is not disclosed in retrieved documents. Free cash flow ≈ dividends received − costs − interest ≈ net income.
Capital allocation in 2025 (illustrative waterfall, EUR M): UCB dividend received 98.1 → less dividend paid 46.3 → less UCB shares bought 4.4 → less overheads/interest ~3 → remainder applied to repaying 41.3 of debt (TUB AR2025 PR, HY2025 PR).
Ratios
Computations by analyst–6.2 data (ROE and ROA on average balances; payout = DPS × 44.51m / net income). ROIC, current ratio, interest coverage, net debt/EBITDA, asset turnover and cash-conversion cycle are not meaningful for a debt-free mono-holding with no operations; interest coverage was high throughout (H1 2025 interest €0.7m vs ~€96m profit).
Trend commentary. The five-year record shows three phases. First, deleveraging (2016–2021): debt fell from €241m to €20m as Tubize retained most of the UCB dividend. Second, re-leveraging to raise the stake (2022–2023): Tubize took debt back up to €79.2m to buy over 1.6m UCB shares and lift its stake from below 35.7% to 36.24% — a deliberate move ahead of UCB's BIMZELX-driven re-rating, which in hindsight created substantial value. Third, a debt-free steady state (2024–2026): debt was repaid in May 2025, top-ups of the stake have shrunk to symbolic amounts (24,487 shares in 2025; 15,783 in H1 2026 at €256.4 average), and the dividend to Tubize shareholders now grows in line with UCB's (+3.8% in 2026). The book-value ROE of ~5% is structurally understated because UCB is carried at cost; on market value, Tubize's earnings yield on its stake is under 1%.
Look-through earnings (analyst construct). Applying Tubize's 36.29% stake to UCB's FY2025 Core EPS of €9.99 (UCB FY2025 PR) gives look-through core earnings of ~€705m (70.57m shares × €9.99), or ~€15.8 per Tubize share — versus reported EPS of €2.09. On H1 2026 Core EPS of €6.84, the half-year look-through figure is ~€483m.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Role | Ownership |
|---|---|---|
Financière de Tubize SA | Listed mono-holding | Free float plus Janssen-family concert |
UCB SA | Listed operating biopharma group | 36.29% held by Tubize (30 Jun 2026) |
Subsidiaries of Tubize | None identified | — |
Per-Share Data and Revenue by Segment
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|---|---|---|
UCB gross DPS received in the year (EUR) | 1.27 | 1.30 | 1.33 | 1.36 | 1.39 | 1.45 |
UCB dividend received (EUR Mn) | — | — | — | — | 98.1 | 102.3 |
Derived UCB dividend received (EUR Mn, DPS × shares held, analyst estimate) | — | — | 92 | 96 | 98.1 | 102.3 |
YoY growth of dividend received (%) | — | — | — | — | — | 4.3 |
Share of total income (%) | 100 | 100 | 100 | 100 | 100 | 100 |
Income Statement and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue / turnover (EUR Mn) | 0 | 0.01 | 0 | 0.01 | 0 |
Dividend income from UCB (EUR Mn) | — | — | — | — | 98.1 |
Operating income (EUR Mn) | -1.54 | -1.82 | -2.14 | -2.24 | — |
Pre-tax income (EUR Mn) | 83.6 | 85.2 | 88.2 | 90.1 | 93.2 |
Net income (EUR Mn) | 83.6 | 85.2 | 88.2 | 90.1 | 93.2 |
EPS basic and diluted (EUR) | 1.88 | 1.91 | 1.98 | 2.02 | 2.09 |
Gross dividend per share declared for the year (EUR) | — | 0.86 | 0.97 | 1.04 | 1.08 |
Net income growth (%) | — | 1.9 | 3.5 | 2.2 | 3.5 |
Dividends & Capital Returns
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Half-year net profit (EUR Mn) | 92.9 | 95.6 | 100.8 |
UCB dividend received (EUR Mn) | — | 98.1 | 102.3 |
Dividend paid to Tubize shareholders (EUR Mn) | — | 46.3 | 48.1 |
Interest expense (EUR K) | — | 719 | 0 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (EUR Mn) | 1,759 | 1,839 | 1,920 | 1,930 | 1,934 |
Financial fixed assets — UCB stake at cost (EUR Mn) | 1,743 | 1,838 | 1,920 | 1,928 | 1,933 |
Cash and short-term investments (EUR Mn) | 15.9 | 1.07 | 0.57 | 1.43 | 1.27 |
Total bank debt — all short-term drawings (EUR Mn) | 20 | 47.8 | 79.2 | 41.3 | 0 |
Long-term debt (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Net debt (EUR Mn; negative = net cash) | 4.1 | 46.7 | 78.6 | 39.9 | -1.3 |
Shareholders' equity (EUR Mn) | 1,705 | 1,752 | 1,797 | 1,840 | 1,886 |
Goodwill and intangibles (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Book value per share (EUR) | 38.3 | 39.4 | 40.4 | 41.3 | 42.4 |
Share Count (M) and Margin Analysis (%)
| Metric | FY2023 | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|---|
UCB shares held (M) | 70.49 | 70.55 | 70.57 | 70.58 |
Stake in UCB (%) | 36.24 | 36.27 | 36.28 | 36.29 |
Tubize market capitalisation (EUR Mn) | — | — | 9,300 | 10,282 |
Dividends & Capital Returns (Annual)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Capex (EUR Mn) | 0 | 0 | 0 | 0 | 0 |
Investment in UCB shares (EUR Mn) | — | — | — | — | 4.4 |
Dividends paid to shareholders (EUR Mn) | — | — | — | — | 46.3 |
Net debt repayment (EUR Mn) | — | — | — | 37.9 | 41.3 |
Buybacks (EUR Mn) | — | — | — | 0 | 0 |
Returns & Leverage Ratios (%)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE on book equity (%) | — | 4.9 | 5.0 | 4.9 | 5.0 |
ROA (%) | — | 4.7 | 4.7 | 4.7 | 4.8 |
Debt / equity (%) | 1.2 | 2.7 | 4.4 | 2.2 | 0 |
Net debt / market value of UCB stake (%) | — | — | — | — | 0 |
Payout ratio (dividend declared / net income, %) | — | 45 | 49 | 51 | 52 |
Solvency ratio (equity / total assets, %) | 96.9 | 95.3 | 93.6 | 95.3 | 97.5 |
Revenue by Region (%)
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Belgium — UCB dividend share of Tubize income (%) | 100 | 100 | 100 |
All other regions (%) | 0 | 0 | 0 |
Revenue by Region and Region Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
UCB total revenue (EUR Mn) | 5,251 | 6,152 | 7,741 |
UCB total revenue growth (%) | -5 | 17 | 26 |
Share Price and Market Valuation
| Metric | FY2023 | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|---|
Period-end share price (EUR) | — | — | 209 | 231 |
Market capitalisation (EUR Mn) | — | — | 9,300 | 10,282 |
Net profit (EUR Mn) | 88.2 | 90.1 | 93.2 | 100.8 |
Gross DPS for the year (EUR) | 0.97 | 1.04 | 1.08 | — |
Valuation Multiples
| Multiple | Tubize (reported) | Tubize (look-through, analyst) | UCB |
|---|---|---|---|
P/E | ~89–110x on statutory EPS (€2.09) | ~11.7x (market cap ~€8.3bn / look-through core earnings ~€705m) | ~18–20x trailing (GuruFocus, Aug 2026) |
P/B | ~4.4–4.8x on book (cost basis) | ~0.53x on NAV (≈47% discount) | ~3.4–3.6x |
EV/EBITDA | n/m | n/m | ~12.9x EV/EBITDA (Simply Wall St, date unspecified) |
EV/Sales | n/m | n/m | ~5x |
Dividend yield | ~0.5% | — | ~0.6–0.7% |
Source Details
| Source | View | Target |
|---|---|---|
Stockopedia consensus | Hold | €230.50 |
KBC Securities (Livio Luyten) | Downgraded Buy → Accumulate (Aug 2025) | — |
TipRanks | "Overvalued" per its model | — |
Per-Share Data and Margin Analysis (%)
| Metric | FY2017 | FY2018 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
Gross dividend per share (EUR) | 0.54 | 0.56 | 0.86 | 0.97 | 1.04 | 1.08 |
YoY growth (%) | — | 3.7 | — | 12.8 | 7.2 | 3.85 |
Analyst Conclusions
Management guidance. Tubize gives no quantitative guidance; it states that it remains attentive to geopolitical developments and their potential impact on UCB and on its own results, with no significant post-balance-sheet events at 30 Jun 2026 (TUB HY2026).
Consensus / underlying expectations. UCB guides FY2026 revenue growth in the low- to mid-teens % and adjusted EBITDA growth in the mid-teens to low-twenties % at CER (UCB HY2026 PR). UCB's dividend has grown 2–4% p.a.; given UCB's earnings step-change (Core EPS €9.99 in FY2025, €6.84 in H1 2026 alone), the board has latitude for faster dividend growth, which would flow directly into Tubize's profit.
Bull case
-
UCB compounding: BIMZELX peak ≥€7bn and EBITDA margin above 40% imply sustained double-digit earnings growth, lifting Tubize's NAV mechanically.
-
Discount mean-reversion: at ~47% vs a long-run 36–42% band, a return to the average would add ~15–20% to Tubize independent of UCB.
-
Free optionality: zero debt plus €350m of lines lets Tubize buy UCB shares after sell-offs (as it did in 2023), accreting NAV per share.
Bear case
-
H2 2026 headwinds: BIMZELX net price erosion, Briviact LOE and higher R&D could cap UCB's share price, as the Jul 2026 reaction showed.
-
Structural discount: single-asset concentration, a ~0.5% yield and family control may keep the discount at or above 50%, as in 2024.
-
Dilution / capital calls: an equity-funded UCB mega-deal would force Tubize to draw debt or accept dilution below 36%.
Key catalysts and monitorables (next 12 months)
Concluding analyst verdict. Financière de Tubize is one of Europe's cleanest holding-company structures: a single asset, no debt, negligible overheads and a stable family anchor that has accompanied UCB for nearly a century. The financial statements are deliberately uninformative — €93.2m of statutory profit in FY2025 says little about a company whose 36.29% stake in UCB carries look-through core earnings of roughly €700m and a market value in the region of €15–16bn. The investment case therefore reduces to two variables: UCB's equity value and the discount at which Tubize trades against it.
On the first, UCB has rarely been in better shape. Revenue grew 26% in FY2025, adjusted EBITDA nearly doubled, H1 2026 margins exceeded 40%, BIMZELX's peak-sales ambition was raised to at least €7bn, and the patent runway extends into the 2030s. The near-term debate — U.S. net pricing after broader BIMZELX access, Briviact generics, and a reinvestment cycle in R&D and M&A — is real, and the market's reaction to UCB's half-year results shows sentiment is now sensitive to execution rather than discovery.
On the second, the discount of roughly 47% computed at early-autumn 2026 prices sits wide of Tubize's long-term averages. The new governance — an independent Chair, two former big-pharma executives, a Vice-Chair dedicated to family relations — signals a more professional holding, but there is no explicit discount-control policy, buyback usage, or payout step-up yet. Without such actions, the discount is more likely to oscillate than close.
The resulting verdict is a constructive but conditional one: Tubize is an efficient, lower-beta, cheaper way to own UCB's growth. The most important monitorables are UCB's FY2026 dividend decision, any Tubize capital-return initiative, and whether Tubize deploys its €350m lines if UCB's shares weaken further.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Compensation |
|---|---|---|---|
Eric Nys (via ENRE SRL) | CEO / Managing Director ("Directeur"); also Head of Investor Relations | Signs Art.74 notifications for Tubize (e.g., 25 Aug 2025); contact for AGM matters since at least 2023 | Not disclosed in retrieved materials; total remuneration covered in annual remuneration report |
Anne Keup | Deputy General Manager | Listed by Euronext/Cofisem (Mar 2025) | — |
Anne Sophie Pijcke | Director / company contact (historical) | Contact on 2017–2018 annual reports; still listed as Euronext contact | — |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Since | Profile |
|---|---|---|---|
Bruno Holthof | Chair (independent) | Chair from 25 Apr 2025 (previously independent director) | — |
Cyril Janssen | Vice-Chair (family) | Vice-Chair from 1 Aug 2025 | Janssen family; co-controls Financière Eric Janssen; manages family-shareholder relations; UCB board member [UCB role recalled] |
Evelyn du Monceau | Director (family) | 1982 | Former Chair of UCB; former director of Solvay and Solvac; member of the Belgian Corporate Governance Committee; holds ~11.26% of Tubize (MarketScreener, 31 Dec 2025) |
Iris Löw-Friedrich | Director | 23 Sep 2025 | MD, PhD; former Head of Development and Chief Medical Officer of UCB; board member of Fresenius SE, Sobi AB, Evotec SE |
Carinne Brouillon | Director | 23 Sep 2025 | 30+ years in healthcare including 21 years at Johnson & Johnson; Board of Managing Directors of Boehringer Ingelheim (Human Pharma) Jan 2020–Sep 2024; Supervisory Board of Munich Re since Apr 2021 |
Gaëtan Hannecart | Former Chair | Left board 25 Apr 2025 | Oversaw generational transition and build-out of management team |
Major Shareholders
| Holder | Stake (%) | Date / source |
|---|---|---|
Financière Eric Janssen SPRL (jointly controlled by Eric and Cyril Janssen) | 23.60 | FSMA notification 30 Dec 2015 (denominator 44,548,598) |
Evelyn du Monceau (incl. Altaï Invest) | 11.26 | MarketScreener, 31 Dec 2025 |
Baron Daniel Janssen (estate/heirs) | 13.19 | FSMA, Mar 2013 (historical; may have changed) |
Barnfin SA (van Rijckevorsel) | 8.64 | FSMA, Mar 2013 (historical) |
Concert total (2013 notification) | 51.98 | FSMA |
Free float (residual, approx.) | ~48 | Derived |
Financière de Tubize | 36 | UCB shareholders page, Oct 2025 |
FMR (Fidelity) | 7.5 | Same |
BlackRock | 6 | Same |
UCB treasury shares | 2 | Same |
Other institutions | 32 | Same |
Retail | 11 | Same |
Competitive Landscape
Key Competitors
| Peer | Type | Relevance to Tubize |
|---|---|---|
UCB SA (direct) | Underlying operating company | Investors choose between UCB direct (no discount, full liquidity) and Tubize (discount, lower liquidity, family governance) |
Solvac SA | Belgian mono-holding (Solvay family) | Closest structural analogue: family-controlled listed holding over a single Belgian listed group |
Groupe Bruxelles Lambert (GBL) | Belgian diversified holding | Benchmark Belgian holding discount |
Sofina SA | Belgian diversified holding (incl. healthcare/life sciences) | Long-term family investor |
Ackermans & van Haaren | Belgian diversified holding | Benchmark |
Brederode SA | Belgian/Luxembourg holding | Benchmark |
Gimv | Belgian listed private equity (life sciences exposure) | Healthcare investment alternative |
Quest for Growth | Belgian listed investment company | Healthcare/tech small-cap exposure |
Investor AB | Swedish holding (Wallenberg) | Pan-European holding benchmark, owns stakes in pharma (AstraZeneca) |
Exor NV | Agnelli family holding | Family-holding benchmark |
Novo Holdings / Lundbeckfonden (unlisted) | Foundation owners of Novo Nordisk / Lundbeck | Governance analogues (stable controlling owners of pharma) |
Competitor Detail
| UCB franchise | Main competitors | Competing products |
|---|---|---|
BIMZELX (IL-17A/F) | AbbVie; Johnson & Johnson; Novartis; Eli Lilly; Amgen | Skyrizi, Rinvoq; Tremfya, Stelara; Cosentyx; Taltz; Otezla |
CIMZIA (anti-TNF) | AbbVie; J&J; Amgen; biosimilar makers | Humira and biosimilars; Simponi, Remicade; Enbrel |
RYSTIGGO / ZILBRYSQ (gMG) | argenx; AstraZeneca/Alexion; J&J | Vyvgart; Ultomiris, Soliris; nipocalimab |
FINTEPLA (rare epilepsy) | Jazz Pharmaceuticals; Takeda; others | Epidiolex; soticlestat (pipeline) |
Epilepsy (Briviact/Vimpat/Keppra) | Generic manufacturers; SK Life Science; Eisai | Generics; Xcopri; Fycompa |
EVENITY (osteoporosis) | Amgen (Prolia); Eli Lilly; Radius | Prolia/biosimilars; Forteo; Tymlos |
Peer Comparison FY2025
| Metric | Tubize | UCB | Solvac | GBL |
|---|---|---|---|---|
Structure | Mono-holding | Operating biopharma | Mono-holding | Diversified holding |
Underlying asset concentration | 1 asset (UCB 36.29%) | — | 1 asset (Solvay) | Multi-asset |
Latest revenue / income | €93.2m net profit FY2025 | €7,741m revenue FY2025 | — | — |
Growth | +3.5% net profit FY2025 | +26% revenue FY2025 | — | — |
Margin | n/m | Adj. EBITDA 34.1% FY2025; 40.7% H1 2026 | n/m | n/m |
R&D intensity | 0% | — | 0% | 0% |
Net debt | Nil (net cash €1.3m YE2025) | — | — | — |



